NCT05357560View on ClinicalTrials.gov

A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Malaria, Plasmodium Falciparum
Interventions
BIOLOGICAL

Matrix-M with RH5.2 VLP and/or R21

3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints

Trial Locations (1)

PO Box 273

Medical Research Council Unit, Fajara, Banjul

All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

collaborator

Medical Research Council Unit, The Gambia

OTHER

lead

University of Oxford

OTHER